There are currently no approved treatments for the increasingly prevalent liver disease non-alcoholic steatohepatitis (NASH), but this looks highly likely to change within the next year.
Earlier this month, it was reported that Zydus Cadila, part of Cadila Healthcare (BOM: 532321), had filed the New Drug Application (NDA) for the NASH treatment saroglitazar magnesium with the Drug Controller General of India (DCGI).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze